S-1/A: Theriva Biologics Announces Proposed Public Offering of Common Stock and Warrants

Theriva Biologics is offering up to 8,403,361 shares of common stock along with warrants in a best efforts offering to raise capital for working capital and general corporate purposes.

Summary

• Theriva Biologics is filing an amendment to its registration statement for a proposed public offering.
• The offering includes up to 8,403,361 shares of common stock and accompanying common warrants, or pre-funded warrants in lieu of common stock, also with accompanying common warrants.
• The assumed public offering price is $1.19 per share of common stock and accompanying common warrant, based on the closing price on March 17, 2025.
• Each common warrant will allow the holder to purchase one share of common stock at an exercise price to be determined, and will expire five years from the issuance date.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership thresholds of 4.99% or 9.99% of the outstanding common stock.
• A.G.P./Alliance Global Partners is acting as the sole placement agent on a best efforts basis.
• The offering is expected to terminate on April 30, 2025, unless terminated earlier.
• The company intends to use the net proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up.
• The company may also use a portion of the proceeds to invest in or acquire other products, businesses, or technologies.
• Directors and officers have agreed to a 90-day lock-up period after the offering.
• The company has agreed to a 60-day standstill on further issuances of common stock or related securities.

Sentiment

Score: 4

Explanation: The document is largely neutral in tone, presenting the details of the offering. However, the inclusion of risk factors and the auditor's going concern warning temper the overall sentiment.

Positives

• The offering aims to strengthen the company's financial position.
• Proceeds will support ongoing research and development efforts.
• The offering provides flexibility for potential strategic investments or acquisitions.

Negatives

• The offering is on a 'best efforts' basis, meaning there's no guarantee all securities will be sold.
• The actual public offering price may be lower than the assumed price of $1.19.
• Investors will experience immediate and substantial dilution.
• There is no established public trading market for the warrants.
• The company has broad discretion in the use of the net proceeds.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's auditors report contains an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company will need to raise additional capital to operate its business.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value of the shares they purchase in this offering and may experience additional dilution in the future.
• This is a reasonable best efforts offering, with no minimum amount of securities required to be sold, and the company may sell fewer than all of the securities offered hereby.
• If the price of the Common Stock fluctuates significantly, your investment could lose value.
• We do not intend to pay dividends on the Common Stock, so any returns will be limited to increases, if any, in the Common Stocks value.
• There is no public market for the Common Warrants or Pre-Funded Warrants to purchase shares of the Common Stock being offered by us in this offering.
• Provisions of the Common Warrants and Pre-Funded Warrants offered by this prospectus could discourage an acquisition of us by a third party.
• We may not receive any additional funds upon the exercise of the Common Warrants or Pre-Funded Warrants.
• If we sell Common Stock or preferred stock in the future, stockholders may experience immediate dilution and, as a result, our stock price may decline.
• Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. We may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although we have no commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.

Industry Context

This offering is a common method for clinical-stage biopharmaceutical companies to raise capital to fund ongoing research and development activities.

Comparison to Industry Standards

• Comparable companies often utilize similar financing strategies, such as issuing common stock and warrants, to fund clinical trials and operations.
• The terms of the offering, including the warrant coverage and exercise price, will likely be compared to recent offerings by similar-sized companies in the biotech sector.
• The use of a best-efforts placement agent is a standard practice for companies with limited access to institutional investors.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from the increased funding for research and development.
• The company's ability to execute its business plan may be enhanced by the additional capital.

Next Steps

• The company will seek to secure commitments from investors for the purchase of the securities.
• The company and the placement agent will determine the final offering price and terms.
• The company will proceed with the closing of the offering, contingent upon market conditions and investor demand.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Theriva Biologics, capital raise, securities, placement agent, AGP, dilution